Therapeutic effects of alprostadil on CCl₄-induced hepatic fibrosis in rats and investigation of its molecular mechanisms.

Authors

Ziqing Shen, Yanfen Zhang, Rongwei Zhao, Xiaowen Yang, Jiarong Guo, Mingyan Dong, Ting Ma, Songyan Ma, Na Sai, Zhiheng Dong

Published in

Molecular and cellular biochemistry. Jun 17, 2026. Epub Jun 17, 2026.

Abstract

Hepatic fibrosis (HF) is driven by hepatic stellate cell (HSC) activation. Although cyclic adenosine monophosphate (cAMP) is a key antifibrotic signal, whether pharmacological cAMP elevation acts through protein kinase A (PKA) or exchange protein directly activated by cAMP 1 (EPAC1) remains unclear. Alprostadil (PGE1) elevates intracellular cAMP, but its antifibrotic mechanism is undefined. Using CCl₄-induced HF in rats and primary HSCs, we found that Alprostadil markedly reduced liver injury, collagen deposition, and HSC activation. Fibrotic livers showed increased total cAMP but decreased PKA- and EPAC1-bound cAMP, indicating depletion of functional cAMP microdomains. Alprostadil restored effector-bound cAMP, increased EPAC1 expression, and enhanced PKA/CREB phosphorylation. Notably, EPAC1 inhibition-but not PKA inhibition-attenuated the antifibrotic effects of Alprostadil in vivo and in vitro. These findings identify EPAC1 as the dominant downstream effector through which Alprostadil restores localized cAMP signaling to suppress HSC activation and hepatic fibrosis.

PMID:
42307830
Bibliographic data and abstract were imported from PubMed on 17 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.